PRINCETON, N.J., Sept. 11, 2019 /PRNewswire/ -- Soligenix,
Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage
biopharmaceutical company focused on developing and commercializing
products to treat rare diseases where there is an unmet medical
need, announced today that it has appointed Jonathan Guarino, as its Senior Vice President
and Chief Financial Officer. Mr. Guarino has over 20 years of
diverse experience in the financial and strategic management of
emerging growth and commercial companies, including in the life
sciences industry. He has a proven track record and expertise in
corporate financial operations, partnerships, as well
as growth financings.
"We are delighted to welcome Jonathan to our team, as we
leverage his combination of financial acumen and commercial and
business experience," stated Christopher J.
Schaber, PhD, President and Chief Executive Officer of
Soligenix. "As we continue to execute our growth strategy, we
are clearly building momentum towards potential commercialization
and the talent we are attracting is an absolute reflection of our
solid progress to date."
Mr. Guarino has had significant experience with both
development-stage and commercial companies. Most recently, he
served as Corporate Controller for Hepion Pharmaceuticals, Inc.
(formerly ContraVir Pharmaceuticals, Inc.), a New Jersey-based public biotechnology company,
where he contributed to the establishment of the financial
infrastructure, as well as assisted with capital fund-raising and
debt financings. Previously, he worked as Controller and
senior manager of technical accounting for Suite K Value Added
Services LLC and Covance, Inc. Prior to these positions, he
held accounting and finance positions of increasing importance with
several companies, including PricewaterhouseCoopers LLP, BlackRock,
Inc. and Barnes & Noble, Inc. Mr. Guarino is a CPA (certified
public accountant) and CGMA (chartered global management
accountant), who received his BS in Business from Montclair State University.
"I am excited about Soligenix's potential to become a commercial
company and am thrilled to be joining the company at this pivotal
time. I look forward to helping the company achieve success
and create additional value," said Mr. Guarino.
Ms. Karen Krumeich, who has
served as Senior Vice President and Chief Financial Officer since
June 16, 2016, will be pursuing new
opportunities effective September 6,
2019. On behalf of the Company and its Board of Directors, we
would like to thank Karen for her many contributions during the
past three years.
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company focused on
developing and commercializing products to treat rare diseases
where there is an unmet medical need. Our Specialized
BioTherapeutics business segment is developing SGX301 as a novel
photodynamic therapy utilizing safe visible light for the treatment
of cutaneous T-cell lymphoma, our first-in-class innate defense
regulator (IDR) technology, dusquetide (SGX942) for the treatment
of oral mucositis in head and neck cancer, and proprietary
formulations of oral beclomethasone 17,21-dipropionate (BDP) for
the prevention/treatment of gastrointestinal (GI) disorders
characterized by severe inflammation including pediatric Crohn's
disease (SGX203) and acute radiation enteritis (SGX201).
Our Public Health Solutions business segment includes active
development programs for RiVax®, our ricin toxin vaccine
candidate and SGX943, our therapeutic candidate for antibiotic
resistant and emerging infectious disease. The development of our
vaccine programs incorporates the use of our proprietary heat
stabilization platform technology, known as
ThermoVax®. To date, this business segment has
been supported with government grant and contract funding from the
National Institute of Allergy and Infectious Diseases (NIAID), the
Biomedical Advanced Research and Development Authority (BARDA), and
the Defense Threat Reduction Agency (DTRA).
For further information regarding Soligenix, Inc., please visit
the Company's website at www.soligenix.com.
This press release may contain forward-looking statements that
reflect Soligenix, Inc.'s current expectations about its future
results, performance, prospects and opportunities, including but
not limited to, potential market sizes, patient populations and
clinical trial enrollment. Statements that are not historical
facts, such as "anticipates," "estimates," "believes," "hopes,"
"intends," "plans," "expects," "goal," "may," "suggest," "will,"
"potential," or similar expressions, are forward-looking
statements. These statements are subject to a number of
risks, uncertainties and other factors that could cause actual
events or results in future periods to differ materially from what
is expressed in, or implied by, these statements. Soligenix
cannot assure you that it will be able to successfully develop,
achieve regulatory approval for or commercialize products based on
its technologies, particularly in light of the significant
uncertainty inherent in developing therapeutics and vaccines
against bioterror threats, conducting preclinical and clinical
trials of therapeutics and vaccines, obtaining regulatory approvals
and manufacturing therapeutics and vaccines, that product
development and commercialization efforts will not be reduced or
discontinued due to difficulties or delays in clinical trials or
due to lack of progress or positive results from research and
development efforts, that it will be able to successfully obtain
any further funding to support product development and
commercialization efforts, including grants and awards, maintain
its existing grants which are subject to performance requirements,
enter into any biodefense procurement contracts with the U.S.
Government or other countries, that it will be able to compete with
larger and better financed competitors in the biotechnology
industry, that changes in health care practice, third party
reimbursement limitations and Federal and/or state health care
reform initiatives will not negatively affect its business, or that
the U.S. Congress may not pass any legislation that would provide
additional funding for the Project BioShield program. In addition,
there can be no assurance as to timing or success of the Phase 3
clinical trial of SGX942 (dusquetide) as a treatment for oral
mucositis in patients with head and neck cancer receiving
chemoradiation therapy or the Phase 3 clinical trial of SGX301
(synthetic hypericin) for the treatment of cutaneous T-cell
lymphoma. There also can be no assurance as to timing or
success of the preclinical/clinical trials
of RiVax®,
that RiVax® will be approved for
the PRV program or the amount for which a PRV
for RiVax® can be sold. These and
other risk factors are described from time to time in filings with
the Securities and Exchange Commission, including, but not limited
to, Soligenix's reports on Forms 10-Q and 10-K. Unless
required by law, Soligenix assumes no obligation to update or
revise any forward-looking statements as a result of new
information or future events.
View original
content:http://www.prnewswire.com/news-releases/soligenix-appoints-jonathan-guarino-as-chief-financial-officer-300915832.html
SOURCE Soligenix, Inc.